|Table of Contents|

Research progress of PARP inhibitors and gene test in metastatic castration-resistant prostate cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 23
Page:
4539-4547
Research Field:
Publishing date:

Info

Title:
Research progress of PARP inhibitors and gene test in metastatic castration-resistant prostate cancer
Author(s):
XIANG FangzhengSU WenhuiZHANG YubingZHENG Fufu
Department of Urology,the First Affiliated Hospital,Sun Yat-sen University,Guangdong Guangzhou 510080,China.
Keywords:
metastatic castration-resistant prostate cancerPARP inhibitorsgene testresearch progress
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2024.23.018
Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) seriously threatens the living quality and survival time of patients with advanced prostate cancer.As the representative of targeted therapy,poly ADP-ribose polymerase (PARP) inhibitors have shown superior efficacy in mCRPC patients with mutations in DNA damage repair related genes in multiple studies.With the comprehensive and in-depth study of the therapeutic mechanisms of PARP inhibitors and the mutation states of genes,the precise program of diagnosis and treatment in mCRPC has been constantly improved and supplemented,hoping to offer the best survival benefit and the mildest adverse reaction to the patients.This review summarizes the research progress of PARP inhibitors monotherapy,combination therapy and gene test in mCRPC in recent years.It discusses the therapeutic efficacy and adverse reactions of PARP inhibitors monotherapy and combination therapy and the guiding significance of gene test,in order to provide clinical reference.

References:

[1]XIA C,DONG X,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants[J].Chinese Medical Journal,2022,135(5):584-590.
[2]樊博,齐盼,苏建志,等.河北医科大学第四医院前列腺癌患者的基线特征与生存分析[J].中国癌症杂志,2020,30(8):620-625.FAN B,QI P,SU JZ,et al.Baseline characteristics and survival analysis of prostate cancer patients in the Fourth Hospital of Hebei Medical University[J].China Oncology,2020,30(8):620-625.
[3]朱耀.中国去势抵抗性前列腺癌诊治专家共识[J].浙江医学,2016,38(14):1133-1136,1145.ZHU Y.Expert consensus on the diagnosis and treatment of denervation-resistant prostate cancer in China[J].Zhejiang Medicine,2016,38(14):1133-1136,1145.
[4]LIU JM,LIN CC,LIU KL,et al.Second-line hormonal therapy for the management of metastatic castration-resistant prostate cancer:a real-world data study using a claims database[J].Scientific Reports,2020,10(1):4240.
[5]FREEDLAND SJ,DAVIS M,EPSTEIN AJ,et al.Real-world treatment patterns and overall survival among men with metastatic castration-resistant prostate cancer(mCRPC) in the US medicare population[J].Prostate Cancer and Prostatic Diseases,2024,27(2):327-333.
[6]SAAD F,CLARKE NW,OYA M,et al.Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer(PROpel):final prespecified overall survival results of a randomised,double-blind,phase 3 trial[J].The Lancet Oncology,2023,24(10):1094-1108.
[7]LORD CJ,ASHWORTH A.PARP inhibitors:Synthetic lethality in the clinic[J].Science,2017,355(6330):1152-1158.
[8]DAN R,VAN ALLEN EM,WU YM,et al.Integrative clinical genomics of advanced prostate cancer[J].Cell,2015,161(5):1215-1228.
[9]RAO A,MOKA N,HAMSTRA DA,et al.Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now[J].Cancers,2022,14(3):801.
[10]DE BONO J,MATEO J,FIZAZI K,et al.Olaparib for metastatic castration-resistant prostate cancer[J].New England Journal of Medicine,2020,382(22):2091-2102.
[11]MATEO J,DE BONO JS,FIZAZI K,et al.Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and/or BRCA2 in the PROfound trial[J].Journal of Clinical Oncology,2024,42(5):571-583.
[12]MATSUBARA N,NISHIMURA K,KAWAKAMI S,et al.Olaparib in patients with mCRPC with homologous recombination repair gene alterations:PROfound Asian subset analysis[J].Japanese Journal of Clinical Oncology,2022,52(5):441-448.
[13]FIZAZI K,PIULATS JM,REAUME MN,et al.Rucaparib or physician’s choice in metastatic prostate cancer[J].New England Journal of Medicine,2023,388(8):719-732.
[14]BRYCE AH,PIULATS JM,REAUME MN,et al.Rucaparib for metastatic castration-resistant prostate cancer(mCRPC):TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy[J].Journal of Clinical Oncology,2023,41(6_suppl):18.
[15]DE BONO JS,MEHRA N,SCAGLIOTTI GV,et al.Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations(TALAPRO-1):an open-label,phase 2 trial[J].The Lancet Oncology,2021,22(9):1250-1264.
[16]SMITH MR,SCHER HI,SANDHU S,et al.Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects(GALAHAD):a multicentre,open-label,phase 2 trial[J].The Lancet Oncology,2022,23(3):362-373.
[17]SCHER HI,FIZAZI K,SAAD F,et al.Increased survival with enzalutamide in prostate cancer after chemotherapy[J].New England Journal of Medicine,2012,367(13):1187-1197.
[18]POLKINGHORN WR,PARKER JS,LEE MX,et al.Androgen receptor signaling regulates DNA repair in prostate cancers[J].Cancer Discovery,2013,3(11):1245-1253.
[19]SCHIEWER MJ,GOODWIN JF,HAN S,et al.Dual roles of PARP-1 promote cancer growth and progression[J].Cancer Discovery,2012,2(12):1134-1149.
[20]GOODWIN JF,SCHIEWER MJ,DEAN JL,et al.A hormone-DNA repair circuit governs the response to genotoxic insult[J].Cancer Discovery,2013,3(11):1254-1271.
[21]ASIM M,TARISH F,ZECCHINI HI,et al.Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer[J].Nature Communications,2017,8:374.
[22]HUSSAIN MHA,KOCHERGINSKY M,AGARWAL N,et al.BRCAAway:A randomized phase 2 trial of abiraterone,olaparib,or abiraterone+olaparib in patients with metastatic castration-resistant prostate cancer(mCRPC) bearing homologous recombination-repair mutations(HRRm)[J].Journal of Clinical Oncology,2024,42(4_suppl):19.
[23]CHI KN,RATHKOPF DE,SMITH MR,et al.Phase 3 MAGNITUDE study:First results of niraparib(NIRA) with abiraterone acetate and prednisone(AAP) as first-line therapy in patients(pts) with metastatic castration-resistant prostate cancer(mCRPC) with and without homologous recombination repair(HRR) gene alterations[J].Journal of Clinical Oncology,2022,40(6_suppl):12.
[24]CHI KN,SANDHU S,SMITH MR,et al.Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations:second interim analysis of the randomized phase Ⅲ MAGNITUDE trial[J].Annals of Oncology,2023,34(9):772-782.
[25]CHI KNN,CASTRO E,ATTARD G,et al.LBA85 Niraparib(NIRA) with abiraterone acetate plus prednisone(AAP) as first-line(1L) therapy in patients(pts) with metastatic castration-resistant prostate cancer(mCRPC) and homologous recombination repair(HRR) gene alterations:Three-year update and final analysis(FA) of MAGNITUDE[J].Annals of Oncology,2023,34:S1326.
[26]AGARWAL N,AZAD AA,CARLES J,et al.Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer(TALAPRO-2):a randomised,placebo-controlled,phase 3 trial[J].The Lancet,2023,402(10398):291-303.
[27]RAO A,HELLER G,RYAN CJ,et al.Alliance A031902(CASPAR):A randomized phase(ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer(mCRPC)[J].Journal of Clinical Oncology,2023,41(6_suppl):TPS277.
[28]JIAO S,XIA W,YAMAGUCHI H,et al.PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression[J].Clinical Cancer Research,2017,23(14):3711-3720.
[29]YU EY,PIULATS JM,GRAVIS G,et al.Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer:Long-term results from the phase 1b/2 KEYNOTE-365 cohort A study[J].European Urology,2023,83(1):15-26.
[30]ANTONARAKIS ES,PARK SH,GOH JC,et al.Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer:The randomized,open-label,phase Ⅲ KEYLYNK-010 trial[J].Journal of Clinical Oncology,2023,41(22):3839-3850.
[31]SUOMINEN MI,FAGERLUND KM,RISSANEN JP,et al.Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models[J].Clinical Cancer Research,2017,23(15):4335-4346.
[32]EMMETT L,CRUMBAKER M,HO B,et al.Results of a prospective phase 2 pilot trial of 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response and patterns of progression[J].Clinical Genitourinary Cancer,2019,17(1):15-22.
[33]ZHENG F,ZHANG Y,CHEN S,et al.Mechanism and current progress of poly ADP-ribose polymerase(PARP) inhibitors in the treatment of ovarian cancer[J].Biomedicine & Pharmacotherapy,2020,123:109661.
[34]SANDHU S,JOSHUA AM,EMMETT L,et al.LuPARP:Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer(mCRPC)[J].Journal of Clinical Oncology,2023,41(16_suppl):5005.
[35]PHILIP CA,LASKOV I,BEAUCHAMP MC,et al.Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors[J].BMC Cancer,2017,17(1):638.
[36]IBRAHIM YH,GARCIA-GARCIA C,SERRA V,et al.PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition[J].Cancer Discovery,2012,2(11):1036-1047.
[37]POOK D,GEYNISMAN DM,CARLES J,et al.A phase Ⅰb,open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer[J].Clinical Cancer Research,2023,29(17):3292-3300.
[38]KUMARESWARAN R,CHAUDARY N,JALUBA K,et al.Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells[J].Radiotherapy and Oncology,2015,116(3):388-391.
[39]HEGAN DC,LU Y,STACHELEK GC,et al.Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130[J].Proceedings of the National Academy of Sciences of the United States of America,2010,107(5):2201-2206.
[40]KAPLAN AR,GUEBLE SE,LIU Y,et al.Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51[J].Science Translational Medicine,2019,11(492):eaav4508.
[41]KIM JW,MCKAY RR,RADKE MR,et al.Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer:the results from national cancer institute 9984[J].Journal of Clinical Oncology,2023,41(4):871-880.
[42]NA R,ZHENG SL,HAN M,et al.Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death[J].European Urology,2017,71(5):740-747.
[43]TRINER D,GRAF R,GJOERUP O,et al.Real-world effectiveness of PARP inhibitors(PARP inhibitors) in metastatic castration-resistant prostate cancer(mCRPC) by genomic homologous recombination repair(HRR) alterations and homologous recombination deficiency signature(HRDsig)[J].Journal of Clinical Oncology,2024,42(4_suppl):186.
[44]DONG B,FAN L,YANG B,et al.Use of circulating tumor DNA for the clinical management of metastatic castration-resistant prostate cancer:A multicenter,real-world study[J].Journal of the National Comprehensive Cancer Network,2021,19(8):905-914.
[45]SANDHU SK,GOTTO G,VERA-BADILLO FE,et al.1835P a prospective study to determine the prevalence of DNA repair defects in patients(pts) with advanced prostate cancer(PC)[J].Annals of Oncology,2023,34:S993.
[46]FALLAH J,XU J,WEINSTOCK C,et al.Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer:A US food and drug administration pooled analysis[J].Journal of Clinical Oncology,2024,42(14):1687-1698.
[47]ATTARD G,SANDHU SK,RATHKOPF D,et al.1806P efficacy of niraparib and abiraterone acetate plus prednisone(NIRA+AAP) in homologous recombination repair gene-altered(HRR+) metastatic castration-resistant prostate cancer(mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial[J].Annals of Oncology,2023,34:S976-S977.
[48]SCOTT RJ,MEHTA A,MACEDO GS,et al.Genetic testing for homologous recombination repair(HRR) in metastatic castration-resistant prostate cancer(mCRPC):challenges and solutions[J].Oncotarget,2021,12(16):1600-1614.
[49]WANG J,ZHAO D,ZHAO J,et al.A0636-exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer[J].European Urology,2024,85:S1569.

Memo

Memo:
-
Last Update: 2024-11-01